[...]Read More...
Location: India, Karnataka, Bengaluru
Total raised: $9.7M
Founded date: 2001
Investors 2
| Date | Name | Website |
| - | ATEL Capit... | atel.com |
| - | CARB-X | carb-x.org |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.12.2024 | - | $7.9M | CARB-X |
| 06.10.2008 | - | $1.8M | ATEL Capit... |
Mentions in press and media 4
| Date | Title | Description |
| 22.12.2024 | GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae | BANGALORE, INDIA / SINGAPORE – Media OutReach Newswire – 23 December 2024 – GangaGen announced today that it has secured the third instalment of its phased funding grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical... |
| 25.11.2008 | GangaGen cultures $5.4M to treat bacterial infections | Biotech firm GangaGen, based in Palo Alto, Calif., brought in $5.4 million in fifth-round funding from ATEL Ventures, Otsuka Pharmaceuticals and ICF Ltd. to develop treatments for bacterial infections. The company specializes in antibiotic-... |
| 09.10.2008 | Biotech Firm GangaGen Gets $1.8M From ATEL Ventures | Bangalore, Canada and US-based biotechnology company GangaGen Inc has raised $1.8 million in second round of funding from , a San Francisco based venture fund. GangaGen is developing bacteriophage-based remedies for some of the bacterial in... |
| 06.10.2008 | GangaGen raises $1.8M for bacteria treatments | GangaGen is a biotech company that’s working on bacteriophages, which are viruses that infect and destroy bacteria. The company raised $1.8 million to develop treatments for antibiotic-resistant bacterial infections like pneumonia and MRSA,... |